Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opening Session Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Creatine

Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers

Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer

Ziftomenib in Relapsed or Refractory NPM1-Mutant AML

Advanced Biliary Tract Cancer Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin